Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 1,
  • 1, 6Email author,
  • 4, 5 and
  • 4, 5
Contributed equally
World Journal of Surgical Oncology201311:149

https://doi.org/10.1186/1477-7819-11-149

Received: 26 March 2013

Accepted: 26 March 2013

Published: 3 July 2013

The original article was published in World Journal of Surgical Oncology 2011 9:59

Correction

After the publication of this work [1], we noticed that we had incorrectly used the term ‘OGX-011’. All instances of OGX-011 in the manuscript should be changed to ‘ASO-CLU’.

We apologise to the readers and OncoGenex Technologies for this oversight and any negative effects that may have resulted from it.

Notes

Authors’ Affiliations

(1)
Surgery, the Affiliated Hospital of Medical College, QingDao University, QingDao, R. P. China
(2)
Pathology, the Affiliated Hospital of Medical College, QingDao University, QingDao, P. R. China
(3)
Molecular Biology, the Affiliated Hospital of Medical College, QingDao University, QingDao, P. R. China
(4)
Hepatobiliary surgery, Tianjin Medical University Cancer Institute and Hospital, Hexi District, Tianjin, China
(5)
Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
(6)
Department of Surgery, the Affiliated Hospital of Medical College, QingDao University, Qingdao, P. R. China

References

  1. Chen : Clusterin confers gmcitabine resistance in pancreatic cancer. World J Surg Oncol. 2011, 9: 59-10.1186/1477-7819-9-59.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Chen et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement